Anodyne develops the HeroPatch, a transdermal delivery system that administers multi-milligram doses of large molecules, enabling tunable pharmacokinetic profiles and room temperature stability. The company focuses on chronic diseases, starting with obesity, by providing easier access to complex formulations and combination therapies.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of drug delivery for chronic diseases often require frequent injections or complex administration procedures, leading to poor patient adherence and suboptimal therapeutic outcomes. Existing transdermal patches struggle to deliver multi-milligram doses of large molecules, limiting their effectiveness for certain medications and combination therapies.
Solution
Anodyne is developing the HeroPatch, a transdermal drug delivery system designed to administer multi-milligram doses of large molecule therapeutics. This technology enables tunable pharmacokinetic profiles, allowing for precise control over drug release and absorption. The HeroPatch utilizes the dry form of active pharmaceutical ingredients (APIs), enhancing formulation possibilities and enabling room temperature stability. By simplifying the delivery of complex formulations and combination therapies, Anodyne aims to improve patient adherence and outcomes in chronic disease management, initially focusing on obesity.
Target Audience
The primary target audience includes patients with chronic diseases, particularly obesity, and healthcare providers seeking improved drug delivery methods to enhance treatment adherence and efficacy.
Features
- Transdermal delivery of multi-milligram doses of large molecules.
- Tunable pharmacokinetic profiles for optimized drug release.
- Formulation using dry-form APIs for enhanced stability.
- Room temperature stability, eliminating the need for refrigeration.
- Capability to deliver combination therapies.